Next, we investigated whether HER2-DC1 i.t. in combination with single anti-HER2 antibody clone is sufficient for the enhanced antitumor activity or required both anti-HER2 antibodies in the HER2pos TUBO tumor model. This evidence concerns the gene ERBB2 and neoplasm.